Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer
暂无分享,去创建一个
K. Awai | K. Fujitaka | Y. Baba | T. Kubota | S. Yamada | T. Yamagami | T. Hasebe | R. Yoshimatsu | Tomohiro Matsumoto | Keigo Chosa | Shota Kondo
[1] J. Goo,et al. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection , 2018, European Radiology.
[2] F. Abtin,et al. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. , 2017, Radiology.
[3] Y. Maehara,et al. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, Anticancer research.
[4] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[5] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[6] H. Saka,et al. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. , 2016, Lung cancer.
[7] T. Nakajima,et al. Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure , 2016, Cancer science.
[8] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[9] Y. Hiraishi,et al. Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer , 2016, Lung.
[10] N. Chen,et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer , 2016, Scientific Reports.
[11] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[12] Y. Yatabe,et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer , 2015, Scientific Reports.
[13] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[14] G. Ferretti,et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC , 2015, Targeted Oncology.
[15] J. Neal,et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.
[16] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[17] C. Chouaid,et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). , 2014, Lung cancer.
[18] N. Girard,et al. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). , 2014, BoneKEy reports.
[19] E. Smit,et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. , 2014, Lung cancer.
[20] Ho Yun Lee,et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. , 2012, Radiology.
[21] J. Vernejoux,et al. Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[23] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[24] K. Murata,et al. CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. , 2006, European journal of radiology.
[25] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[26] A. Manhire,et al. Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies. , 2002, The British journal of radiology.
[27] B. Daly,et al. Real-time CT fluoroscopy: evolution of an interventional tool. , 1999, Radiology.
[28] K. Katada,et al. Guidance with real-time CT fluoroscopy: early clinical experience. , 1996, Radiology.
[29] W. Sinner. Complications of Percutaneous Transthoracic Needle Aspiration Biopsy , 1976, Acta radiologica: diagnosis.
[30] D. Vanel,et al. Percutaneous CT-guided biopsy of the musculoskeletal system: results of 2027 cases. , 2011, European journal of radiology.
[31] G. Exner,et al. Metastatic bone disease from occult carcinoma: a profile , 2004, International Orthopaedics.